UP!

ANTH $0.07   View long term graphs

Anthera Pharmaceuticals, Inc.
Type
Public
Traded as NASDAQ: ANTH
Industry Pharmaceuticals
Founded 2004
Headquarters Hayward, California, U.S.
Key people
Craig Thompson
(President and CEO)
Website Anthera.com

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase (Sollpura), Anthera’s leading drug candidate which is being developed for exocrine pancreatic insufficiency (EPI) is currently in Phase 3 clinical trials, and A-623 (Blisibimod) for the treatment of IgA nephropathy is currently in Phase 2 clinical trial.

July 2014, Anthera acquired Sollpura (Liprotamase) from Eli Lilly and Company. Sollpura is an investigational pancreatic enzyme replacement therapy (PERT) that uses three biotechnology-derived digestive enzymes intended to treat patients with endocrine pancreatic insufficiency as a result of cystic fibrosis and other diseases.

News

Anthera Pharmaceuticals, Inc. 2.35% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2018 2018-11-05 Future report Set alerts
Q2 2018 2018-08-07 Future report Set alerts
Q1 2018 2018-05-15 -0.57 0.00
Q4 2017 2018-03-05 -0.73 -0.73
Q3 2017 2017-11-06 -0.58 -0.58
Q2 2017 2017-08-09 0.03 0.03
Q1 2017 2017-05-10 -2.03 -2.00
Q4 2016 2017-02-27 -3.20 -2.88
Q3 2016 2016-11-04 -4.88 -4.88
Q2 2016 2016-08-09 -2.80 -2.80

Ratings

2016-07-08 Initiated Coverage HC Wainwright Buy $10.00
2016-06-30 Reiterated Rating Jefferies Group Buy
2016-06-20 Reiterated Rating FBR & Co. Hold
2016-06-20 Reiterated Rating FBR & Co Hold
2016-06-09 Reiterated Rating Jefferies Group Buy
2016-03-11 Lower Price Target Piper Jaffray Overweight $14.00 to $10.00
2016-03-11 Lower Price Target Piper Jaffray Cos. Overweight $14.00 to $10.00
2016-02-19 Lower Price Target Citigroup Inc. $15.00 to $11.00
2016-02-19 Reiterated Rating Jefferies Group Buy $12.00 to $9.00
2015-09-17 Initiated Coverage Citigroup Inc. Buy $15.00
2015-09-15 Reiterated Rating Piper Jaffray Overweight $14.00
2015-09-08 Initiated Coverage SunTrust Buy $14.00
2015-09-08 Initiated Coverage SunTrust Banks Inc. Buy $14.00
2015-05-20 Upgrade Citigroup Inc. Neutral
2015-05-12 Upgrade Citigroup Inc. Sell to Neutral
2015-03-30 Boost Price Target Piper Jaffray $7.50
2015-03-17 Reiterated Rating Jefferies Group Buy $18.00 to $12.00
2012-06-29 Downgrade Ascendiant Capital Markets Buy to Neutral $2.50 to $0.90
2012-06-28 Downgrade JMP Securities Mkt Outperform to Mkt Perform
2012-06-13 Initiated JMP Securities Mkt Outperform $4
2012-06-04 Initiated Ascendiant Capital Markets Buy $2.50
2012-04-26 Initiated MLV & Co Buy $4.50
2012-03-12 Reiterated Canaccord Genuity Buy $13 to $6
2011-12-02 Initiated Collins Stewart Buy $13
2011-11-01 Initiated Deutsche Bank Buy $14
2011-08-01 Downgrade Wedbush Outperform to Neutral $9 to $7
2010-10-20 Initiated MP Advisors Outperform $9
2010-10-06 Initiated Wedbush Outperform $8
2016-07-08 Initiated Coverage HC Wainwright Buy $10.00
2016-06-30 Reiterated Rating Jefferies Group Buy
2016-06-20 Reiterated Rating FBR & Co. Hold
2016-06-20 Reiterated Rating FBR & Co Hold
2016-06-09 Reiterated Rating Jefferies Group Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In ANTH 0 funds of 2183 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
ORBIMED ADVISORS LLC 32.85%  (7462000) AGLE / AMBI / ANTH / ATHX / BOLD / BONE / CRVS / CTIC / ICPT / KALA / LOXO / MRTX / OTIC / RLYP / ROKA / SIEN / SUPN / SYBX / XLRN /
VANTAGEPOINT VENTURE ASSOCIATES IV LLC 23.59%  (5357528) ANTH / GCAP / WAGE /
Thompson David E. 0.56%  (128201) ANTH /
LOWE CHRISTOPHER P. Chief Financial Officer & CBO 0.48%  (108915) ANTH / HNSN /
HENNEY CHRISTOPHER S 0.44%  (100000) ANTH / CYCC / ONTY / PRTA /
SOFINNOVA VENTURE PARTNERS VI L P 0.20%  (44969) ANTH / OCRX /
HEALY JAMES 0.14%  (32443) ANTH / DRTX / HPTX / ITMN / KBIO /
Hislop Colin Chief Medical Officer 0.14%  (31647) ANTH / VSAR /
KILFOIL GEORGINA SVP, Prod. Dev. & Project Mngm 0.13%  (30035) ANTH /
THOMPSON JOHN CRAIG President & COO 0.09%  (19848) ANTH / TTPH /
TRUEX PAUL F President and CEO 0.07%  (16793) ANTH / CBAY /
Mueller Brian 0.04%  (10000) ANTH / BMRN /
DZIURZYNSKI BOGDAN 0.04%  (10000) ANTH / DNDN /
ODINK DEBRA Chief Technology Officer 0.03%  (7896) ANTH /
LIU MAY Chief Accounting Officer 0.03%  (7302) ANTH /

Comments